Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

quote:

BioTics schreef op 30 oktober 2018 12:31:

Bevestiging.

quote:

1 2 3 schreef op 30 oktober 2018 12:33:

al die koersdoelen, erg leuk allemaal en nu ?

quote:

beeldscherm schreef op 30 oktober 2018 12:21:

voor de komende tijd hoeven we ons voor Lanatroep/Takezooi geen zorgen te maken vwb bij evt. voorschrijven hebben ze een " precertification required " nodig

Preauthorization. A decision by your health insurer or plan that a health care service, treatment plan, prescription drug or durable medical equipment is medically necessary. Sometimes called prior authorization, prior approval or precertification.

quote:

bikes schreef op 30 oktober 2018 11:56:

waarom zoveel in de bied?

quote:

BioTics schreef op 30 oktober 2018 12:42:

woutjuhh, goed advies: bereid je voor, lees het eea, want zo speel je met vuur.

quote:

Pharming is hot schreef op 30 oktober 2018 12:25:

First Berlin – Pharming Group NV Research Update (30/10/2018)
30 Oct 2018 By First Berlin Equity Research News
First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY rating and maintained his EUR 2.00 price target.

Abstract
Pharming's share price is down almost 40% on its highest closing prices this year of €1.57 reached on both 18 June and 30 January. In our view the reasons are three consecutive quarters (Q4/17-Q2/18) of flat sales of the recombinant human C1-inhibitor, Ruconest, the non-approval by the FDA of the product for prophylaxis in mid-September, and a general increase in risk aversion over the past few weeks. Last Thursday's news of a 30% sales jump in Q3/18 vs. Q2/18 has so far produced an 8.7% recovery in the stock price. We see more share price upside in coming quarters due to a) further growth in the number of hereditary angioedema (HAE) patients using Ruconest b) rich newsflow on the development of Ruconest in additional and underserved indications such as contrast-induced nephropathy, cardiac protection, pre-eclampsia, delayed graft function, and hemorrhagic shock. Each of these indications is potentially much more valuable than HAE. Investors should also note that competing C1-inhibitors are plasma-based. Plasma supplies are hardly sufficient to serve the HAE market, let alone the markets which Pharming is targeting with its more scalable recombinant product. c) leveraging of the recombinant platform to generate new drug candidates for diseases such as Pompe and Fabry d) generation of additional clinical data to secure approval for Ruconest in HAE prophylaxis. We maintain our Buy recommendation with a price target of €2.00.